Sarcopenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008–2011)

Yong-ho Lee, Kyu Sik Jung, Seung Up Kim, Hye-jin Yoon, Yu Jung Yun, Byung-Wan Lee, Eun Seok Kang, Kwang-Hyub Han, Hyun Chul Lee, Bong-Soo Cha

PII: S0168-8278(15)00176-2
DOI: http://dx.doi.org/10.1016/j.jhep.2015.02.051
Reference: JHEPAT 5608

To appear in: Journal of Hepatology

Received Date: 21 November 2014
Revised Date: 20 February 2015
Accepted Date: 25 February 2015


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008–2011)

Yong-ho Lee¹, Kyu Sik Jung¹,², Seung Up Kim¹,², Hye-jin Yoon¹, Yu Jung Yun¹, Byung-Wan Lee¹, Eun Seok Kang¹, Kwang-Hyub Han¹,², Hyun Chul Lee¹, Bong-Soo Cha¹

¹Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; ²Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea

Word counts: Abstract 250, Total 5194

Figures: 6, Tables: 2

Address all correspondence and requests for reprints to:

Bong-Soo Cha, MD, PhD
Department of Internal Medicine,
Yonsei University College of Medicine,
50 Yonsei-ro, Seodaemun-Gu, Seoul 120-752, South Korea

E-mail: bscha@yuhs.ac
Tel:+82-2-2228-1962, Fax:+82-2-393-6884
Abbreviations: NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; KNHANES, Korea National Health and Nutrition Examination Survey; ASM, appendicular skeletal muscle mass; SMI, skeletal muscle mass index; SD, standard deviation; BMI, body mass index; HSI, hepatic steatosis index; CNS, comprehensive NAFLD score; LFS, NAFLD liver fat score; HOMA-IR, homeostasis model assessment of insulin resistance; AST, aspartate transaminase; ALT, alanine transaminase; AOR, adjusted odds ratio.

Financial support: No

Authors' contributions

Study concept and design: Y.Lee, B.S.Cha.


Drafting of the manuscript: Y.Lee, B.S.Cha.

Critical revision of the manuscript for important intellectual content: K.S.Jung, S.U.Kim, B-W.Lee, H.C.Lee, K-H.Han, E.S.Kang.


Administrative, technical, or material support: B-W.Lee, E.S.Kang, H.C.Lee, K-H.Han, B.S.Cha.
ABSTRACT

Background & Aims: Although sarcopaenia is associated with obesity-related comorbidities, its influence on non-alcoholic fatty liver disease (NAFLD) or steatohepatitis has not been fully determined. We aimed to investigate the direct relationship between sarcopaenia and NAFLD or steatohepatitis in the general population.

Methods: We conducted a cross-sectional study using nationally representative samples of 15,132 subjects from the Korea National Health and Nutrition Examination Surveys 2008–2011. Subjects were defined as having NAFLD when they had higher scores from previously validated NAFLD prediction models such as the hepatic steatosis index, comprehensive NAFLD score and NAFLD liver fat score. BARD and FIB-4 scores were used to define advanced fibrosis in subjects with NAFLD. The skeletal muscle index (SMI) [SMI(%)=total appendicular skeletal muscle mass (kg) / weight (kg)×100] measured by dual-energy X-ray absorptiometry was used to diagnose sarcopaenia with cut points of 32.2% for men and 25.5% for women.

Results: SMI was inversely correlated with all NAFLD predicting scores (Ps<0.001). After stratification, sarcopaenic subjects had an increased risk of NAFLD regardless of obesity (odds ratios [ORs]=1.55 to 3.02, depending on models; all Ps<0.001) or metabolic syndrome (ORs=1.63 to 4.00, all Ps<0.001). Multiple logistic regression analysis also demonstrated this independent association between sarcopaenia and NAFLD after adjusting for confounding factors related to obesity or insulin resistance (ORs=1.18 to 1.22, all Ps<0.001). Furthermore, among the NAFLD population, subjects with lower SMIs were likely to have advanced fibrosis compared with non-sarcopaenic individuals (BARD and FIB-4: ORs=1.83 and 1.69, respectively; both Ps<0.001). Compared with non-exercised subjects, individuals who
exercised regularly had a lower risk of NAFLD (P<0.001), particularly among obese people with well-preserved muscle mass.

**Conclusions:** Sarcopaenia is associated with increased risks of NAFLD and advanced fibrosis, independent of obesity or metabolic control.

Keywords: sarcopaenia, NAFLD, steatohepatitis, obesity
Introduction

Ageing is becoming a critical public health issue worldwide, particularly in developed societies, as the elderly population has been remarkably increasing. An annual report published by the World Health Organisation announced that an average of 22% of the population in high-income countries in 2011 were aged older than 60 years: 31% in Japan, the nation with the highest percentage, 20% overall in Europe and 19% in the United States [1]. Ageing gradually causes the decline in physical function and activity, which are linked to frailty, resulting in a substantial burden on the public health care system as well as impairment in the quality of life for individuals [2]. As one of the key components of frailty, sarcopaenia is regarded as a geriatric syndrome characterised by progressive and generalised loss of skeletal muscle mass and strength [3,4]. Recently, the concept of sarcopaenia is changing: it is now recognised not as an inevitable outcome of ageing, but as a disease condition which could be overcome [5]. Sarcopaenia is more prevalent among elderly people with obesity and exists with various comorbidities [5]. Several cardiometabolic disorders, including diabetes mellitus, metabolic syndrome, and cardiovascular disease, have been associated with sarcopaenia [3,6-8].

Non-alcoholic fatty liver disease (NAFLD) is one of the most common metabolic liver disorders with an estimated prevalence of ~30% in developed countries [9-11], and its incidence is expected to rise rapidly in the future as the rate of obesity increases, populations become aged, and sedentary lifestyles prevail. NAFLD and sarcopaenia share a similar aetiology such as insulin resistance, which may be ameliorated by the beneficial effect of exercise [12]. Among the categories of NAFLD, non-alcoholic steatohepatitis (NASH) shows a deteriorating nature of chronic liver disease and is associated with increased liver-related
mortality by elevating the risk of liver fibrosis, cirrhosis and hepatocellular carcinoma [13-15]. Advanced liver cirrhosis may induce skeletal muscle loss by reducing protein synthesis with increased protein breakdown in muscle [12].

A recent study reported a strong relationship between sarcopenia and NAFLD, suggesting sarcopenia as a new risk factor of NAFLD [16]. However, a substantial effect of obesity on NAFLD was not considered and adequately adjusted in this study, which assessed the relationship of NAFLD with sarcopenic obesity rather than with sarcopenia itself [17]. Considering the concept that insulin resistance and obesity are the common denominators between sarcopenia and NAFLD, more robust investigation is necessary to determine the complex association of sarcopenia with NAFLD. Therefore, we analysed data from the Korea National Health and Nutrition Examination Survey (KNHANES), which is a nationwide cross-sectional study with a nationally representative sample of Korean population annually conducted by the Korea Centre for Disease Control and Prevention to regularly assess the health and nutritional status of general civilians. The aim of this study was to investigate whether the association between sarcopenia and NAFLD is independent of obesity or metabolic syndrome in the general population. We further evaluated the association between sarcopenia and NASH in subjects with NAFLD.

Methods

Study participants

The KNHANES is a nationwide, population-based and cross-sectional health examination and survey regularly conducted by the Division of Chronic Disease Surveillance
of the Korea Centres for Disease Control and Prevention in the Ministry of Health and Welfare to monitor the general health and nutrition status of South Koreans, as previously described in detail [18]. Similar to the National Health and Nutrition Examination Survey in the United States, each KNHANES is composed of independent datasets of participants from the general population of South Korea. All of the participants were randomly assigned from 600 randomly selected districts of cities and provinces in South Korea.

As depicted in Supplementary Fig. 1, of 37,753 participants from the KNHANES 2008–2011, we initially selected those aged ≥20 years (12,160 men and 15,911 women). Subjects with missing data for the appendicular skeletal muscle mass (ASM) were excluded (N=9,382). In addition, subjects who met the following criteria were excluded based on our protocol: (1) alcohol consumption >140 g/week for men and 70 g/week for women (N=2898); (2) positive serologic markers for hepatitis B (N=561) or hepatitis C virus (N=28); and (3) the presence of liver cirrhosis (N=42). This excluded population (N=3,557) was later used for a sensitive analysis. Finally, 15,132 participants (5,617 men and 9,515 women) were included in the analysis and were divided into four groups according to the presence of sarcopenia and obesity. Written informed consent was secured from all of the participants before the study began, and the KNHANES was conducted following ethical approval by the Institutional Review Board of the Korea Centre for Disease Control and Prevention (No: 2008-04EXP-01-C, 2009-01CON-03-2C, 2010-02CON-21-C, 2011-02CON-06C).

Measurements of the appendicular skeletal muscle mass

As previously described [18], ASM was measured using Dual-Energy X-ray
Absorptiometry (DXA, QDR 4500A; Hologic Inc., Bedford, MA, USA). The skeletal muscle mass index (SMI) was calculated as follows: SMI (%) = total ASM (kg) / body weight (kg) × 100 [16], which was modified from the study of Janssen et al. [19]. This formula was applied based on previous evidence that placing the body weight in the denominator was the best method to minimise the effect of the strong correlation between ASM and body weight [20]. Sarcopenia was defined as <1 standard deviation (SD) below the sex-specific average for a young reference population from the datasets of KNHANES 2008–2011 (960 men and 1240 women, aged 20–30 years) [6,20]. The cut-off points for sarcopenia were 32.2% for men and 25.5% for women.

**Measurements of clinical parameters and biochemical analysis**

KNHANES examined participant demographics and personal and family medical history, including data on anthropometrics, smoking history, physical activity and reproductive health (e.g., early menopause and history of oestrogen replacement therapy) from standardised health questionnaires. Smoking status was categorised as never, ex- and current smoker by self-reporting. Regular exercise was defined as engaging in vigorous exercise on a regular basis (≥20 min at a time and at least three times per week) [18]. Subjects were considered as obese when the body mass index (BMI) was ≥25 kg/m² based on the criteria of the Asian-Pacific region [21]. Diabetes mellitus was defined based on (1) using insulin or oral hypoglycaemic agents or (2) fasting plasma glucose ≥126 mg/dl. Impaired fasting glucose was defined as a fasting plasma glucose level of 100–125 mg/dl [22]. Participants were diagnosed as hypertensive if the systolic pressure was ≥140 mmHg, if the
diastolic pressure was ≥90 mmHg, or if current antihypertensive medication was used.

After overnight fasting for at least 8 h, blood specimens collected from each subject were processed and transported in cold storage to the Central Testing Institute (Neodin Medical Institute, Seoul, Korea). All of the blood samples were analysed within 24 h after transportation. Serum 25-hydroxyvitamin D (25\([\text{OH}]D\)) concentration was determined by radioimmunoassay (DiaSorin Inc., Stillwater, MN, USA) using a gamma counter (1470 Wizard; PerkinElmer, Turku, Finland). The serum levels of creatinine and the lipid and liver enzyme profiles were determined using a Hitachi 7600 automated chemistry analyser (Hitachi, Tokyo, Japan) using specific indicated methods. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula. The estimated glomerular filtration rate (GFR) was derived from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [23].

**Definition of hepatic steatosis and advanced fibrosis**

NAFLD was defined using previous validated fatty liver prediction models [10,24,25] as follows: (1) hepatic steatosis index (HSI) [24]; (2) comprehensive NAFLD score (CNS) [10]; (3) NAFLD liver fat score (LFS) [25]. The BARD [26] and FIB-4 [27] scores were selected as a surrogate index for defining severe conditions of NAFLD (advanced fibrosis). The calculations of BARD and FIB-4 were conducted only in subjects with NAFLD defined using NAFLD prediction models. All prediction models were summarized in Supplementary table 1.
**Statistical analysis**

The characteristics of the study subjects were analysed according to the status of obesity and sarcopaenia using Student’s *t*-test for continuous variables and χ² test for categorical variables. Differences in prevalence of NAFLD were assessed using χ² test with Bonferroni adjustments. The association between SMI and fatty liver prediction scores (HSI, CNS and LFS) was evaluated using Chi-square test after transformation of these variables into quartiles. To exclude the effect of obesity or metabolic syndrome, the study population was stratified into two groups depending on the presence of either obesity or metabolic syndrome. Differences in fatty liver prediction scores were also compared using Student’s *t*-test. Multivariable logistic regression analysis was applied to determine the independent association between sarcopaenia and NAFLD after adjustment for age and sex in model 1 or age, sex, regular exercise, homeostasis model assessment of insulin resistance (HOMA-IR), smoking, and hypertension in model 2. Continuous and categorical variables were expressed as the mean ± SD and N (%), respectively. A *p*-value less than 0.05 was considered to be statistically significant. Statistical analyses were performed using SPSS version 20.0 for Windows (IBM Corp., Armonk, NY, USA).
Results

Participant characteristics according to the status of obesity and sarcopaenia

From KNHANES 2008–2011, 15,132 individuals were analysed in the present study. Baseline characteristics of the study participants are presented in Table 1 separately according to the status of obesity and sarcopaenia in order to investigate whether the association between NAFLD and sarcopaenia is independent of obesity. The prevalence of sarcopaenia showed a large discrepancy between the non-obese and obese populations (19% for non-obese vs. 53% for obese individuals; P<0.001). Regardless of obesity status, sarcopaenic subjects were older and had higher BMIs, fasting glucose levels and index values of insulin resistance (HOMA-IR) than non-sarcopaenic individuals. Worse lipid profiles and kidney function were observed in sarcopaenic subjects. Moreover, sarcopaenic subjects showed an increased proportion of cardiometabolic disorders, including impaired fasting glucose, diabetes, hypertension and metabolic syndrome and tended not to exercise regularly. Aspartate transaminase (AST) levels were higher in sarcopaenic subjects regardless of obesity, whereas alanine transaminase (ALT) levels were significantly elevated only in sarcopaenic subjects with BMI<25 kg/m².

Hepatic steatosis was significantly increased in subjects with sarcopaenia regardless of obesity and metabolic syndrome.

The estimated prevalence of NAFLD was 22 to 29% in the overall study population depending on the NAFLD prediction models (Table 2). SMI, which indicates the degree of peripheral skeletal muscle mass, showed a strong negative relationship with all indices.
predicting NAFLD (all P<0.001; Fig. 1). Because obesity and insulin resistance were well-established risk factors for NAFLD as well as sarcopaenia, we examined the independent association of sarcopaenia with NAFLD after stratification with obesity or metabolic syndrome which reflects clinical condition of insulin resistance. Both non-obese and obese subjects with sarcopaenia showed a significantly increased proportion of NAFLD, irrespective of the different NAFLD prediction models (Table 1 and Fig. 2A). Depending on the prediction models applied, 9~30% (60~83%) of non-obese (obese) subjects with sarcopaenia were likely to have NAFLD (Fig. 2A, Supplementary Fig. 2A and B). Regardless of having metabolic syndrome, a higher prevalence of NAFLD was found in sarcopaenic individuals than in non-sarcopaenic subjects (Fig. 2B, Supplementary Fig. 2C and D). Particularly, among people without metabolic syndrome, a 2.3- to 3.3-fold increase in the proportion of NAFLD was observed in sarcopaenic subjects compared with non-sarcopaenic subjects (15~31% vs. 7~10%, respectively; P<0.001). With respect to NAFLD-predicting indices, subjects with sarcopaenia had significantly higher values of HSI, CNS and LFS regardless of obesity and metabolic syndrome (Fig. 3 and Supplementary Fig. 3). Furthermore, AST and ALT levels were significantly increased in individuals with sarcopaenia independent of metabolic syndrome, but only in the non-obese population (Fig. 4). Consistent with the results of the inverse relationship between SMI and NAFLD predicting indices (Fig. 1), subjects with a higher SMI tended to have lower levels of ALT and AST (All Ps<0.001, Supplementary Fig. 4).

*Sarcopaenia is independently associated with non-alcoholic or alcoholic fatty liver disease and hepatic steatosis with chronic hepatitis.*
To adjust for conventional confounding covariates that affect NAFLD, a multivariable logistic regression model was applied (Table 2). In a minimally adjusted model (Model 1) with age and sex, sarcopenic subjects had a markedly higher risk for NAFLD than non-sarcopenic subjects regardless of the NAFLD prediction models (adjusted odds ratios [AORs] ranging from 2.9 to 4.3; all Ps<0.001). This association remained significant even after the adjustment for established risk factors of NAFLD, including BMI, diabetes status, triglyceride levels and insulin resistance as shown in Model 2, although AORs were reduced further to 1.2 (all Ps<0.05).

As a sensitivity analysis, we explored whether this relationship persists in individuals with excessive alcohol consumption or underlying chronic liver disease condition (N=3557) who were initially excluded from the analysis (Supplementary Table 2). Similarly, an independent association between sarcopenia and hepatic steatosis was observed in this specific population with different characteristics (AORs ranging from 1.1 to 1.5; all Ps<0.05).

**Relationship between NAFLD and exercise according to the presence of sarcopenia and obesity.**

To examine the impact of exercise on NAFLD in subjects with sarcopenia, the proportion of NAFLD was assessed among individuals who did or did not exercise regularly after stratification with the status of obesity and sarcopenia (Fig. 5 and Supplementary Fig. 5). Among obese people with preserved skeletal muscle mass, subjects who conducted exercise regularly were less likely to have NAFLD, regardless of NAFLD prediction models (46% in regularly exercised subjects vs. 55% in non-exercised subjects; P<0.001).
sub-groups, there was no statistical significance, although people who regularly exercised were less likely to have NAFLD.

**Association of sarcopaenia with hepatic fibrosis in subjects with NAFLD**

To further evaluate the relationship between sarcopaenia and steatohepatitis, non-invasive indices of hepatic fibrosis were calculated in individuals with NAFLD. The average scores of BARD and FIB-4, which both reflect the degree of fibrosis, were significantly increased in subjects with sarcopaenia compared with those in non-sarcopaenic subjects (BARD: 1.87 vs. 1.35; FIB-4: 0.99 vs. 0.85, all P<0.001, Fig. 6 and Supplementary Fig. 6). When the validated cut-off points to predict hepatic fibrosis were applied in this population, sarcopaenic patients were more likely to be categorised as having advanced fibrosis than non-sarcopaenic controls, regardless of the prediction methods (BARD: 60% vs. 45%, P<0.001; FIB-4: 22% vs. 14%, P<0.001).
Discussion

This nationally representative, population-based study demonstrated that subjects with sarcopaenia had a higher risk of NAFLD independent from the status of obesity as well as metabolic syndrome compared with individuals with a preserved muscle mass. Furthermore, the degree of the fatty liver condition which was determined by elevated markers of liver fibrosis was much more severe, in subjects with a lower skeletal muscle mass among individuals with NAFLD. People who exercised regularly were less likely to have NAFLD, defined by indirect measures, only under the condition of obesity and a well-preserved muscle mass. Considering previous concerns that sarcopaenic subjects tend to have a larger fat mass, a condition that may convey the confounding effect of muscle mass on NAFLD [17], we clearly established evidence that a decreased muscle mass is significantly associated not only with NAFLD but also with its severity. In addition, sarcopaenic subjects with alcoholic liver disease or chronic viral hepatitis had an increased risk of fatty liver after the adjustment for other confounding variables.

Consistent with previous findings [10,16], liver enzymes and obesity-related parameters such as, BMI, waist circumference, and glycaemic and lipid profiles were inversely associated with SMI but positively related to fatty liver prediction scores (data not shown), indicating that the NAFLD scores and sarcopaenia index are interrelated. Although the pathogenic processes of developing sarcopaenia have not been fully understood, sarcopaenia and NAFLD share common pathophysiologic mechanisms and similar phenotypes. Increased insulin resistance, which is a major causative factor of NAFLD [28], can also aggravate sarcopaenia via mitochondrial dysfunction and the degradation of muscle protein by the activation of the ubiquitin-proteasome proteolytic pathway [12]. As insulin is a
strong anabolic hormone to stimulate muscle hypertrophy via intracellular Akt/mTOR pathway. Impairment in insulin signalling (insulin resistance) can diminish the synthesis of muscle protein [12]. Furthermore, this condition can also result in elevation of circulating levels of free fatty acids by lipolysis from adipose tissues, which in turn leads to inhibit growth hormone/insulin growth factor-1 axis that plays a favourable role in protection against age-related muscle loss and in muscle regeneration [12,29]. Patients with chronic liver disease or cirrhosis are reported to have a lower level of insulin growth factor-1, while increased levels of various cytokines such as tumour necrosis factor-α and transforming growth factor-β, which are closely involved in sarcopenia [30]. In addition, obesity triggers oxidative stress with chronic inflammation and the dysregulation of adipokines secreted from subcutaneous or visceral fats, which contribute to the development of ectopic fat accumulation in the liver and loss of skeletal muscle mass [12,31]. Considering that skeletal muscle is the major insulin-responsive target organ, sarcopenia can further promote insulin resistance and reduce energy expenditures [32], which may lead to the development of NAFLD. Therefore, insulin resistance and inflammation can contribute to a complex of vicious cycles between NAFLD and sarcopenia.

However, our findings demonstrated that sarcopenia was associated with higher values of NAFLD markers in non-obese people or subjects without metabolic syndrome, suggesting a possibility that sarcopenia itself is linked to NAFLD independent of insulin resistance or obesity. Skeletal muscle is considered an endocrine organ that secretes peptides called myokines that can mediate crosstalk among metabolic tissues such as the liver [33]. Among several myokines, interleukin-6 showed a protective effect on the development of NAFLD in inflammation-prone animal models [34] and irisin, an exercise-inducible myokine
was inversely associated with the degree of fatty liver in obese humans [36]. Therefore, it is plausible that muscle could play a causative role for fatty liver by secreting various myokines. It is well known that exercise has a significant benefit on the improvement in hepatic steatosis regardless of weight loss [37]. We found that regular exercise was associated with a lower levels of NAFLD-predicting markers only in obese subjects without sarcopaenia, suggesting that a preserved muscle mass may be required to exert benefits towards the amelioration of fatty liver such as exercise-induced release of healthy myokines. Further study should be necessary to support this hypothesis.

Histologically, fatty liver is defined as the accumulation of excessive fat >5% of the liver weight. Although a liver biopsy is currently the gold standard for the diagnosis of hepatic steatosis and its severity, imaging modalities are widely used in clinical practice instead due to the invasive nature of biopsy. However, radiological modalities such as ultrasonography or computed tomography are rather inaccurate because milder degrees of steatosis (<33% of fat in hepatocytes) cannot be fully detected [38]. Furthermore, without biopsy, NASH or advanced fibrosis is hardly distinguished using imaging assessments as well as ALT levels. To overcome this limitation, several non-invasive fibrosis scoring models were developed and validated [10,26,39]. In the present study, we applied several well-validated scoring systems to detect NAFLD in the general population or advanced fibrosis in patients with NAFLD. Among the many models for predicting NAFLD, three risk models—HSI, CNS, and LFS—were selected based on their high areas under the curve (0.86, 0.89, 0.82, respectively) to detect NAFLD in Korean subjects [10]. We used BARD and FIB-4 scores, which are validated in patients with biopsy-proven NAFLD [26,40] and have clinically significant implications in NAFLD-related outcomes [41,42]. Interestingly, our data
demonstrated that subjects with sarcopaenia had a higher level of liver fibrosis markers regardless of the NASH predicting model. However, extra caution should be needed in interpreting these results, due to possible bias from applying indirect markers of NAFLD or NASH.

The current study had several strengths. First, our robust investigation provided strong evidence of a close relationship between sarcopaenia and NAFLD without the involvement of either obesity or insulin resistance. Because NAFLD is highly affected by obesity, it is indispensable to distinguish the impact of sarcopaenia alone from sarcopaenic obesity on fatty liver. In addition, stratification for obesity was necessary because the prevalence of sarcopaenia was markedly different between obese and non-obese subjects. Second, our sensitivity analyses showed that sarcopaenic subjects with alcoholic liver disease or chronic viral hepatitis had an increased risk of fatty liver, suggesting the extensive role of sarcopaenia on other chronic liver diseases. Furthermore, this was a large population-based analysis using well-examined national data, which strengthens the statistical reliability of the results and generalisability of the data. Finally, for the first time, we focused on the association of low muscle mass with advanced fibrosis as reflected by several indices in subjects with NAFLD. According to the two-hit NAFLD/NASH model, key elements for triggering steatohepatitis or fibrosis are underlying oxidative stress and chronic inflammation [43], which can also deteriorate the degradation of muscle mass [12].

However, the current study has some limitations, which should be complemented by further investigation. First, due to the unavailable data of hepatic imaging or biopsy, we used operational criteria for defining NAFLD or advanced fibrosis based on several predicting models that have been well validated [10,44-46]. Second, this cross-sectional study design
did not allow us to make solid conclusions regarding the causal relationships between sarcopaenia and NAFLD or NASH. Finally, we applied the measurements of the skeletal muscle mass only to define sarcopaenia and did not evaluate muscle function, although a consensus of standardised diagnostic criteria for sarcopaenia has not been entirely established.

In conclusion, this nationwide survey of a representative sample of the Korean population demonstrated that sarcopaenia was significantly associated not only with higher values of NAFLD-predicting markers but also with severe conditions of hepatic steatosis independent from condition of obesity or insulin resistance. Considering the worldwide increase of ageing and obesity societies, prospective studies are warranted to elucidate the complex causal relationship between a low skeletal muscle mass and NAFLD or NASH.

**Disclosure of potential conflicts of interest**

All authors state that they have no conflicts of interest.

**Acknowledgments**

The authors are very grateful to officers who conducted KNHANES.
Figure legends

**Fig. 1.** The association of the skeletal muscle index by quartiles with different fatty liver scores by quartiles. (A) Hepatic steatosis index (HSI), (B) Comprehensive NAFLD score (CNS), (C) Liver fat score (LFS).

**Fig. 2.** The difference in the prevalence of NAFLD according to the sarcopenic status after stratification for obesity or metabolic syndrome. (A) The prevalence of NAFLD by status of sarcopenia and obesity, or metabolic syndrome, (B) The prevalence of NAFLD by status of sarcopenia and metabolic syndrome.

**Fig. 3.** The difference in the hepatic steatosis index according to the sarcopenic status after stratification for obesity or metabolic syndrome. (A) The hepatic steatosis index by status of sarcopenia and obesity, or metabolic syndrome, (B) The hepatic steatosis index by status of sarcopenia and metabolic syndrome.

**Fig. 4.** The difference in serum levels of transaminases according to the sarcopenic status after stratification for obesity or metabolic syndrome. (A and B) Serum levels of ALT, (C and D) Serum levels of AST. The data are presented as the mean ± SE. *P<0.001, **P<0.01, and ***P<0.05. MS, metabolic syndrome.

**Fig. 5.** The difference in the prevalence of NAFLD according to the status of sarcopenia and
exercise after stratification for obesity.

**Fig. 6.** The association between hepatic fibrosis and sarcopenia in subjects with NAFLD. The difference in the BARD (A) and FIB-4 (B) scores according to the sarcopenic status. The data are presented as the mean ± SD. The proportion of subjects with hepatic fibrosis as defined by BARD (C) or FIB-4 (D) scores according to the sarcopenic status.

Table 1. Characteristics of the study participants according to the status of obesity and sarcopenia

Table 2. Adjusted odds ratios (AORs) with 95% confidence intervals (CIs) of non-alcoholic fatty liver disease (NAFLD) assessed by different predictive models
References


[17] Kim SW, Jung HW. Which one is associated with nonalcoholic fatty liver disease?: Small muscle mass or large fat mass. Hepatology 2014.


Osteoporos Int 2013.


[42] Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers


Fig 6

A

B

C

D

P<0.001

P<0.001

Hepatic fibrosis by BARD (%)

Hepatic fibrosis by FIB-4 (%)

Non-sarcopenic  Sarcopenic

Non-sarcopenic  Sarcopenic
Table 1. Characteristics of the study participants according to the status of obesity and sarcopaenia

<table>
<thead>
<tr>
<th></th>
<th>Non-obese (N=10479)</th>
<th>Obese (N=4653)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Non-sarcopenic (N=8475)</td>
<td>Sarcopenic (N=2004)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>47.9 ± 16.8</td>
<td>56.7 ± 16.3</td>
</tr>
<tr>
<td>Sex (female), N(%)</td>
<td>5469 (65)</td>
<td>1307 (65)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>21.6 ± 2.1</td>
<td>22.8 ± 1.6</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>114.1 ± 17.3</td>
<td>120.4 ± 18.5</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>72.3 ± 10.0</td>
<td>74.2 ± 10.3</td>
</tr>
<tr>
<td>ASM (kg)</td>
<td>17.7 ± 4.3</td>
<td>15.4 ± 3.6</td>
</tr>
<tr>
<td>SMI (%)</td>
<td>31.1 ± 4.1</td>
<td>26.5 ± 3.3</td>
</tr>
<tr>
<td>ASM/Ht² (kg/m²)</td>
<td>6.7 ± 1.0</td>
<td>6.0 ± 0.9</td>
</tr>
</tbody>
</table>

Biochemistry

|                  |  |  |  |  |  |  |  |  |  |
|------------------|----------------------|---------------|
| Fasting glucose (mg/dL) | 94.0 ± 19.8 | 99.7 ± 25.3 | <0.001 | 100.7 ± 23.8 | 105.1 ± 27.6 | <0.001 |
| Fasting insulin (µIU/mL) | 8.8 ± 4.1 | 10.1 ± 6.8 | <0.001 | 11.6 ± 5.1 | 12.8 ± 6.8 | <0.001 |
| HOMA-IR          | 2.1 ± 1.2           | 2.5 ± 3.1    | <0.001 | 2.9 ± 1.7 | 3.4 ± 2.9 | <0.001 |
| Total cholesterol (mg/dl) | 182.8 ± 34.0 | 193.3 ± 36.4 | <0.001 | 193.5 ± 36.1 | 198.6 ± 37.2 | <0.001 |
| HDL cholesterol (mg/dl) | 49.6 ± 11.1 | 46.8 ± 10.7 | <0.001 | 43.5 ± 9.3 | 44.1 ± 9.7 | 0.040 |
| Triglycerides (mg/dl)⁷ | 109.1 ± 79.2 | 134.3 ± 85.9 | <0.001 | 155.9 ± 107.2 | 159.4 ± 95.0 | 0.002 |
| LDL cholesterol (mg/dl) | 110.9 ± 29.7 | 119.8 ± 32.6 | <0.001 | 119.9 ± 31.6 | 124.2 ± 33.6 | <0.001 |
| AST (IU/L)       | 20.7 ± 9.2           | 21.5 ± 7.5   | 0.004 | 23.3 ± 10.0 | 24.3 ± 10.9 | 0.002 |
| ALT (IU/L)       | 17.9 ± 11.5          | 19.9 ± 12.1  | <0.001 | 26.3 ± 18.7 | 27.1 ± 20.0 | 0.159 |
| Creatinine (mg/dl) | 0.8 ± 0.2 | 0.8 ± 0.3 | 0.712 | 0.9 ± 0.2 | 0.8 ± 0.3 | <0.001 |
| eGFR (mL/min/1.73m²) | 96.8 ± 17.3 | 92.1 ± 19.2 | <0.001 | 92.6 ± 16.3 | 90.1 ± 18.5 | <0.001 |
| 25(OH)D (ng/ml)  | 18.4 ± 7.1           | 17.4 ± 6.7   | <0.001 | 19.3 ± 6.8 | 17.9 ± 6.5 | <0.001 |

Clinical parameters
<table>
<thead>
<tr>
<th>Condition</th>
<th>N(%)</th>
<th>Mean ± SD</th>
<th>Log transformed</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFG/diabetes, N(%)</td>
<td>1270/530 (15/6)</td>
<td>415/291 (21/15)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension, N(%)</td>
<td>1691 (20)</td>
<td>759 (38)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Metabolic syndrome, N(%)</td>
<td>1184 (14)</td>
<td>628 (31)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking (Past/Current), N(%)</td>
<td>868/1406 (10/17)</td>
<td>225/251 (11/13)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Regular exercise, N(%)</td>
<td>1237 (15)</td>
<td>201 (10)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Residence (Metro/City/Rural), %</td>
<td>45/34/21</td>
<td>43/36/21</td>
<td>0.093</td>
</tr>
<tr>
<td>Hepatic steatosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>assessed by HSI, N(%)</td>
<td>349 (4)</td>
<td>178 (9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>assessed by CNS, N(%)</td>
<td>732 (10)</td>
<td>419 (25)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>assessed by LFS, N(%)</td>
<td>1153 (14)</td>
<td>609 (30)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data for continuous variables were expressed as mean ± SD. *Log transformed.

ASM, appendicular skeletal muscle mass; Ht, height; SMI, skeletal muscle index; eGFR, estimated glomerular filtration rate; IFG, impaired fasting glucose; HSI, hepatic steatosis index; CNS, comprehensive NAFLD score; LFS, liver fat score.
Table 2. Adjusted odds ratios (AORs) with 95% confidence intervals (CIs) of non-alcoholic fatty liver disease (NAFLD) assessed by different predictive models

<table>
<thead>
<tr>
<th>NAFLD (N, %)</th>
<th>NAFLD assessed by HSI (N=3292, 22%)</th>
<th>NAFLD assessed by CNS (N=4270, 28%)</th>
<th>NAFLD assessed by LFS (N=4360, 29%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variables</td>
<td>AOR</td>
<td>95% CI</td>
<td>P</td>
</tr>
<tr>
<td>Sarcopenia</td>
<td>4.26</td>
<td>3.91–4.63</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Adjusted model 1*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarcopenia</td>
<td>1.18</td>
<td>1.03–1.34</td>
<td>0.014</td>
</tr>
<tr>
<td>BMI, per 1 kg/m²</td>
<td>2.53</td>
<td>2.43–2.62</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Regular exercise</td>
<td>0.83</td>
<td>0.74–0.94</td>
<td>0.002</td>
</tr>
<tr>
<td>Triglycerides, per 50mg/dl</td>
<td>1.15</td>
<td>1.11–1.18</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Glycemic status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal fasting glucose</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Impaired fasting glucose</td>
<td>1.15</td>
<td>0.99–1.34</td>
<td>0.068</td>
</tr>
<tr>
<td>Diabetes</td>
<td>8.27</td>
<td>6.74–10.16</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Logistic models are adjusted for age and sex.
Logistic models are adjusted for age, sex, regular exercise, HOMA-IR, smoking, and hypertension status.